Earning Call Transcript

AI summary - Q1 FY27 revenue INR756 Cr +37% y-y; EBITDA INR111 Cr +60.7% y-y; PAT INR64.5 Cr +89.9% y-y - Non-ibuprofen pharma products grew 67% y-y, contributing 43% of pharma revenue vs 36% last year - Export revenue rose to 28.5% of total; NMPA approval for clopidogrel in China expands market - FY27 guidance: 15-20% revenue growth, EBITDA margin 14-15%, exports 25-30% of revenue - Capex ~INR200 Cr annually; 60% for expansion/new products, 40% for efficiency - Broad-based pharma growth driven by higher capacity utilization (80-95%) and operational efficiency - Chemical segment margins improved; capacity increased for ethyl acetate and acetic anhydride - New product Triacetin started production; revenue potential ~INR120 Cr/year - Management confident in sustaining growth and margin expansion; no material one-offs in Q1